|Bid||0.0000 x 1400|
|Ask||0.0000 x 1800|
|Day's Range||1.7700 - 1.8500|
|52 Week Range||1.5000 - 24.4000|
|Beta (3Y Monthly)||2.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Neuralstem, Inc. (NASDAQ:CUR) share pric...
GERMANTOWN, Md., March 22, 2019 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem.
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, appointed Kenneth C. Carter, Ph.D., as the Company’s Executive Chairman of the Board to be effective on January 1, 2019. Dr. Carter will replace interim CEO, Jim Scully, who will be stepping down. “Dr. Carter brings a wealth of drug development expertise and executive leadership having led both private and public biotechnology companies.
Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome - - Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke - -.
If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...